Talus Bio Analysis: $11M Raised
What is Talus Bio?
Talus Bio specializes in making the regulome visible, focusing on measuring and modulating gene regulators in live cells. Their proprietary technology allows for unprecedented access to drug targets that were previously hidden, enabling the development of first-in-class medicines. This innovative approach transforms drug discovery by unlocking new therapeutic possibilities in various disease areas.
Location
550 17th Ave, Suite 550, Seattle, Washington 98122, United States
Employees
11-50
Founded
2020
Revenue
$1-5M
Funding Status
Seed
Product Features & Capabilities
- MARMOT platform for targeting transcription factors, functional proteomics, automated biology, machine learning for drug development, focus on hard-to-treat transcription factor proteins.
Use Cases
Identify novel drug targets in oncology and rare diseases; Develop first-in-class therapeutics targeting transcription factors; Accelerate preclinical development through toxicity prediction; Collaborate on drug discovery with innovative biotech teams; Explore gene regulation mechanisms in live cell contexts.
How much Talus Bio raised
1 - $11.2 million
August 20, 2024Lead Investor: Two Bear Capital
Who are the founders of Talus Bio
AF
Alex Federation
Founder
LP
Lindsay Pino
CTO
Investors
- Two Bear Capital
- WRF Capital
- NFX
- YC Continuity Fund
- Funders Club VC
- BoxOne Ventures
Competitors Overview
Talus Bioscience operates in the biotechnology sector, focusing on drug development for gene regulators, particularly targeting transcription factors involved in cancer. Its main competitors include:
- Ciscovery Bio: Focuses on non-coding genomics and cis-regulatory modules (CRMs) to enhance g
Business Model
Venture capital funding and grants for drug discovery targeting undruggable diseases.
Market Focus
Talus Bioscience primarily focuses on the biotechnology industry, specifically in the areas of functional proteomics and cancer research, utilizing automated biology and machine learning to target transcription factor proteins involved in cancer and other diseases.
Other Considerations
Raised $11.2M in additional funding in 2024; Collaborates with teams pushing the boundaries of biology; Focuses on previously undruggable targets in various disease areas.
See something that needs updating? Suggest edits to this profile.